Clinical trial
A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma.
NCT05804032 is registered in ClinicalTrials.gov with University of Heidelberg Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Non-inferiority Trial Assessing Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma.
- Lead sponsor
- University of Heidelberg Medical Center
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 14, 2023
- Completion date
- January 30, 2026
- Enrollment
- 514 (actual)
- Sites
- 91
Conditions
As the registry lists them; a condition with its own page is linked.